ARP2/3 complex affects myofibroblast differentiation and migration in pancreatic ductal adenocarcinoma

Yifeng Sun,Yina Qiao,Yiqi Niu,Bindhu Kollivayal Madhavan,Chao Fang,Jingxiong Hu,Kathleen Schuck,Benno Traub,Helmut Friess,Ingrid Herr,Christoph W. Michalski,Bo Kong
DOI: https://doi.org/10.1002/ijc.35246
2024-10-30
International Journal of Cancer
Abstract:What's New? Cancer‐associated fibroblasts (CAFs) have distinct pro‐tumorigenic actions that affect the development and progression of pancreatic ductal adenocarcinoma (PDAC). Here, the authors replicated events of early pancreatic carcinogenesis in vitro and in vivo to better understand CAF migration in PDAC. CAF migration and myofibroblast differentiation in PDAC were found to be regulated by the ARP2/3 complex, which functions in actin cytoskeleton organization and lamellipodia formation. Experiments further indicate that ARP2/3 inhibition reduces CAF motility and TGFβ1‐mediated differentiation and uncovers a fibroblast migration‐related transcriptional signature linked to poor patient survival. The findings present ARP2/3 as a novel therapeutic target for PDAC treatment. The ARP2/3 complex, which orchestrates actin cytoskeleton organization and lamellipodia formation, has been implicated in the initiation of pancreatic ductal adenocarcinoma (PDAC). This study aims to clarify its impact on the activity of cancer‐associated fibroblasts (CAFs), key players in PDAC progression, and patient outcomes. Early pancreatic carcinogenesis was modeled in p48Cre; LSL‐KrasG12D mice with caerulein‐induced pancreatitis, complemented by in vitro studies on human immortalized pancreatic stellate cells (PSCs) and primary PDAC‐derived CAFs. Data were gained from microarray analysis, RNA sequencing (RNA‐seq), and single‐cell RNA sequencing (sc‐RNA‐seq), with subsequent bioinformatics analysis. We uncovered a specific transcriptional signature associated with fibroblast migration in early pancreatic carcinogenesis and linked it to poor survival in patients with PDAC. A pivotal role of the ARP2/3 complex in CAF migration was identified. Inhibition of the ARP2/3 complex markedly decreased CAF motility and induced significant morphological changes in vitro. Furthermore, its inhibition also hindered TGFβ1‐mediated myofibroblastic CAF differentiation but had no effect on IL‐1‐mediated inflammatory CAF differentiation. Our findings position the ARP2/3 complex as central to the migration and differentiation of myofibroblastic CAF. Targeting this complex presents a promising new therapeutic avenue for PDAC treatment.
oncology
What problem does this paper attempt to address?